MacroGenics, Inc.
Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
Last updated:
Abstract:
The present invention is directed to a polypeptide (for example, an antigen-binding molecule) that comprises a polypeptide portion of a deimmunized serum-binding protein capable of binding to said serum protein. The presence of the serum-binding protein extends the serum half-life of the polypeptide, relative to the serum half-life of the polypeptide if lacking the polypeptide portion of the deimmunized serum-binding protein. The invention also pertains to methods and uses that employ such molecules.
Status:
Application
Type:
Utility
Filling date:
28 Jun 2019
Issue date:
26 Mar 2020